Synagis
E474951
Synagis is a monoclonal antibody medication used to help prevent serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biologic drug
ⓘ
medication ⓘ monoclonal antibody ⓘ |
| bindsTo | RSV F protein ⓘ |
| hasActiveIngredient | palivizumab ⓘ |
| hasApprovalYear | 1998 ⓘ |
| hasATCCode | J06BB16 ⓘ |
| hasBrandName | Synagis NERFINISHED ⓘ |
| hasDosage | 15 mg/kg once monthly ⓘ |
| hasFormulation | solution for injection ⓘ |
| hasGenericName | palivizumab NERFINISHED ⓘ |
| hasIndication |
prevention of RSV disease in high-risk infants
ⓘ
prevention of RSV disease in high-risk young children ⓘ prevention of serious lower respiratory tract infection caused by respiratory syncytial virus ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction | neutralizes respiratory syncytial virus and inhibits fusion with host cells ⓘ |
| hasMolecularType | humanized monoclonal antibody ⓘ |
| hasPharmacologicClass |
antiviral monoclonal antibody
ⓘ
immunologic agent ⓘ |
| hasPregnancyCategory | not established for use in pregnancy ⓘ |
| hasRouteOfAdministration |
intramuscular
ⓘ
parenteral ⓘ |
| hasSeriousAdverseEffect |
anaphylaxis
ⓘ
severe hypersensitivity reaction ⓘ |
| hasSideEffect |
fever
ⓘ
injection site reactions ⓘ rash ⓘ upper respiratory tract infection ⓘ |
| hasTargetPopulation |
high-risk infants
ⓘ
high-risk young children ⓘ |
| isAdministeredAs | monthly intramuscular injection during RSV season ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isAdministeredDuring | RSV season ⓘ |
| isApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| isContraindicatedIn | patients with history of severe hypersensitivity to palivizumab ⓘ |
| isGivenBy | intramuscular injection into anterolateral thigh ⓘ |
| isIndicatedFor |
certain high-risk children up to 24 months of age
ⓘ
infants with chronic lung disease of prematurity ⓘ infants with hemodynamically significant congenital heart disease ⓘ premature infants ⓘ |
| isMarketedBy | AstraZeneca NERFINISHED ⓘ |
| isNotRecommendedFor | routine use in healthy full-term infants ⓘ |
| isNotUsedFor |
treatment of acute RSV disease
ⓘ
treatment of established RSV infection ⓘ |
| isProducedBy | recombinant DNA technology ⓘ |
| isUsedFor | prophylaxis of RSV infection ⓘ |
| reduces | risk of RSV-related hospitalization in high-risk infants ⓘ |
| targets | respiratory syncytial virus NERFINISHED ⓘ |
| wasDevelopedBy | MedImmune NERFINISHED ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.